Pharming Group NV (OTCMKTS:PHGUF – Get Free Report)’s share price hit a new 52-week low on Monday. The stock traded as low as $0.9285 and last traded at $0.9285, with a volume of 1,603 shares changing hands. The stock had previously closed at $1.1050.
Pharming Group Stock Performance
The firm has a market cap of $623.09 million, a price-to-earnings ratio of 77.38 and a beta of 0.42. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.39. The company has a 50 day moving average of $1.13 and a 200 day moving average of $1.29.
About Pharming Group
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases and other conditions with limited treatment options. The company was founded in 1988 and has built its business around therapies produced using recombinant technology.
Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially life-threatening swelling.
Featured Articles
- Five stocks we like better than Pharming Group
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
